IL6 and COVID-19: Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19, C-reactive protein (CRP), lactate dehydrogenase (LDH), and D-dimer levels and T cell counts, and it has been suggested that Tocilizumab, with its inhibitory effect on IL-6, may be effective in treatment of COVID-19 (10, 11).